Home
EPRX
EPRX News

Latest EUPRAXIA PHARMACEUTICALS INC (EPRX) News on July 14, 2025

Eupraxia Pharmaceuticals Announces Voting Results from Annual General and Special Meeting of Shareholders

GlobeNewswire

a month ago

Eupraxia Pharmaceuticals Announces Voting Results from Annual General and Special Meeting of Shareholders

“Bear-Pit Session” Highlights Peterson Capital’s Canada Growth Conference in Montreal

GlobeNewswire

2 months ago

“Bear-Pit Session” Highlights Peterson Capital’s Canada Growth Conference in Montreal

Eupraxia Pharmaceuticals to Host Virtual KOL Event to Discuss the Phase 1b/2a RESOLVE Study of EP-104GI for the Treatment of Eosinophilic Esophagitis (EoE) on May 9, 2025

GlobeNewswire

2 months ago

Eupraxia Pharmaceuticals to Host Virtual KOL Event to Discuss the Phase 1b/2a RESOLVE Study of EP-104GI for the Treatment of Eosinophilic Esophagitis (EoE) on May 9, 2025

Eupraxia Pharmaceuticals Reports First Quarter 2025 Financial Results

GlobeNewswire

2 months ago

Eupraxia Pharmaceuticals Reports First Quarter 2025 Financial Results

Eupraxia Pharmaceuticals Announces Sustained Positive Treatment Outcomes in Patients with Eosinophilic Esophagitis (EoE) After Nine Months of Receiving EP-104GI

GlobeNewswire

2 months ago

Eupraxia Pharmaceuticals Announces Sustained Positive Treatment Outcomes in Patients with Eosinophilic Esophagitis (EoE) After Nine Months of Receiving EP-104GI

GlobeNewswire

3 months ago

Eupraxia Pharmaceuticals to Present at Investor and Scientific Conferences in April and May

$TSX Penny Stock Highlights Calfrac Well Services And Two More Compelling Picks$

Simply Wall St.

3 months ago

TSX Penny Stock Highlights Calfrac Well Services And Two More Compelling Picks

Here's Why We're Watching Eupraxia Pharmaceuticals' (TSE:EPRX) Cash Burn Situation

Simply Wall St.

4 months ago

Here's Why We're Watching Eupraxia Pharmaceuticals' (TSE:EPRX) Cash Burn Situation

Eupraxia Pharmaceuticals Reports Fourth Quarter 2024 Financial Results

PR Newswire

4 months ago

Eupraxia Pharmaceuticals Reports Fourth Quarter 2024 Financial Results

Eupraxia Pharmaceuticals Announces Positive Data from RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic Esophagitis

CNW Group

5 months ago

Eupraxia Pharmaceuticals Announces Positive Data from RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic Esophagitis

Craig-Hallum starts Eupraxia at Buy, sees ‘significant upside’ potential

TipRanks

5 months ago

Craig-Hallum starts Eupraxia at Buy, sees ‘significant upside’ potential

Eupraxia Pharmaceuticals Announces CFO Succession

CNW Group

5 months ago

Eupraxia Pharmaceuticals Announces CFO Succession

Eupraxia's DiffuSphere™ Technology Demonstrates Targeted Drug Release while Minimizing Systemic Exposure for a Period of More Than Six Months

CNW Group

8 months ago

Eupraxia's DiffuSphere™ Technology Demonstrates Targeted Drug Release while Minimizing Systemic Exposure for a Period of More Than Six Months

Eupraxia Pharmaceuticals to Present at American College of Rheumatology Convergence 2024 Annual Meeting

PR Newswire

8 months ago

Eupraxia Pharmaceuticals to Present at American College of Rheumatology Convergence 2024 Annual Meeting

Eupraxia Pharmaceuticals to Present at American College of Rheumatology Convergence 2024 Annual Meeting

CNW Group

8 months ago

Eupraxia Pharmaceuticals to Present at American College of Rheumatology Convergence 2024 Annual Meeting

Eupraxia Pharmaceuticals' CEO Dr. James Helliwell to Participate in Webinar Event, "Eosinophilic Esophagitis: The Emerging Digestive Disorder Frequently Misdiagnosed", on November 15, 2024

PR Newswire

8 months ago

Eupraxia Pharmaceuticals' CEO Dr. James Helliwell to Participate in Webinar Event, "Eosinophilic Esophagitis: The Emerging Digestive Disorder Frequently Misdiagnosed", on November 15, 2024

Eupraxia Pharmaceuticals Announces Positive Data from Fifth Cohort of RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic Esophagitis

CNW Group

8 months ago

Eupraxia Pharmaceuticals Announces Positive Data from Fifth Cohort of RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic Esophagitis

Eupraxia Pharmaceuticals Reports Third Quarter 2024 Financial Results

PR Newswire

8 months ago

Eupraxia Pharmaceuticals Reports Third Quarter 2024 Financial Results

Eupraxia Pharmaceuticals Announces that it has Closed a Non-Brokered Private Placement of C$44.5 Million

PR Newswire

8 months ago

Eupraxia Pharmaceuticals Announces that it has Closed a Non-Brokered Private Placement of C$44.5 Million

Eupraxia Pharmaceuticals to Present at American College of Gastroenterology Annual Scientific Meeting 2024

CNW Group

9 months ago

Eupraxia Pharmaceuticals to Present at American College of Gastroenterology Annual Scientific Meeting 2024

Lancet Rheumatology Publishes Phase 2b Data on Eupraxia Pharmaceuticals' EP-104IAR for the Treatment of Knee Osteoarthritis

CNW Group

9 months ago

Lancet Rheumatology Publishes Phase 2b Data on Eupraxia Pharmaceuticals' EP-104IAR for the Treatment of Knee Osteoarthritis

Lancet Rheumatology Publishes Phase 2b Data on Eupraxia Pharmaceuticals' EP-104IAR for the Treatment of Knee Osteoarthritis

PR Newswire

9 months ago

Lancet Rheumatology Publishes Phase 2b Data on Eupraxia Pharmaceuticals' EP-104IAR for the Treatment of Knee Osteoarthritis

Eupraxia Pharmaceuticals to Present at United European Gastroenterology Week 2024

CNW Group

9 months ago

Eupraxia Pharmaceuticals to Present at United European Gastroenterology Week 2024

Eupraxia Pharmaceuticals to Present at United European Gastroenterology Week 2024

PR Newswire

9 months ago

Eupraxia Pharmaceuticals to Present at United European Gastroenterology Week 2024

Eupraxia Pharmaceuticals Strengthens Senior Management Team

PR Newswire

9 months ago

Eupraxia Pharmaceuticals Strengthens Senior Management Team

Eupraxia Pharmaceuticals to Present at 20th ISDE World Congress for Esophageal Diseases

PR Newswire

10 months ago

Eupraxia Pharmaceuticals to Present at 20th ISDE World Congress for Esophageal Diseases

Eupraxia Pharmaceuticals Announces Data from RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic Esophagitis

CNW Group

10 months ago

Eupraxia Pharmaceuticals Announces Data from RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic Esophagitis

Eupraxia Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference

CNW Group

10 months ago

Eupraxia Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Eupraxia Pharmaceuticals Reports Second Quarter 2024 Financial Results

CNW Group

a year ago

Eupraxia Pharmaceuticals Reports Second Quarter 2024 Financial Results

Eupraxia Pharmaceuticals Reports Second Quarter 2024 Financial Results

PR Newswire

a year ago

Eupraxia Pharmaceuticals Reports Second Quarter 2024 Financial Results

Eupraxia Pharmaceuticals Announces New C$12 Million Convertible Debt Facility

CNW Group

a year ago

Eupraxia Pharmaceuticals Announces New C$12 Million Convertible Debt Facility

Eupraxia Pharmaceuticals to Present at Controlled Release Society 2024 Annual Meeting and Expo

PR Newswire

a year ago

Eupraxia Pharmaceuticals to Present at Controlled Release Society 2024 Annual Meeting and Expo

Eupraxia Pharmaceuticals to Present at Controlled Release Society 2024 Annual Meeting and Expo

CNW Group

a year ago

Eupraxia Pharmaceuticals to Present at Controlled Release Society 2024 Annual Meeting and Expo

Eupraxia Pharmaceuticals' CEO Dr. James Helliwell to Participate in Webinar Event, "Exploring the Rapid Rise of Osteoarthritis" on July 9, 2024

CNW Group

a year ago

Eupraxia Pharmaceuticals' CEO Dr. James Helliwell to Participate in Webinar Event, "Exploring the Rapid Rise of Osteoarthritis" on July 9, 2024

A Data-Driven Analysis of Netflix's Streaming Dominance and Future Outlook

GuruFocus.com

a year ago

A Data-Driven Analysis of Netflix's Streaming Dominance and Future Outlook

Energy Global

a year ago

ANDRITZ to equip new Silvan hydropower plant in Türkiye

Supreme Court Justice Alito talks polarization, his wife talks revenge in secret recordings

USA TODAY

a year ago

Supreme Court Justice Alito talks polarization, his wife talks revenge in secret recordings

Pacer ETFs Rings in its 9th Anniversary as Firm nears $50 Billion in Assets Under Management

Business Wire

a year ago

Pacer ETFs Rings in its 9th Anniversary as Firm nears $50 Billion in Assets Under Management

Indra Energy Drives Sustainability Focus through the Penguins Pledge with the Pittsburgh Penguins

Business Wire

a year ago

Indra Energy Drives Sustainability Focus through the Penguins Pledge with the Pittsburgh Penguins

SEALSQ to Launch Two New Quantum Resistant Chips

GlobeNewswire

a year ago

SEALSQ to Launch Two New Quantum Resistant Chips

Shrinking Fed rate cut expectations to keep US Treasury yields elevated: Reuters poll

Reuters

a year ago

Shrinking Fed rate cut expectations to keep US Treasury yields elevated: Reuters poll

Global Upstream Bioprocessing Market Analysis Report 2024-2030: A $59.24 Billion Market by 2030, Registering a CAGR of 14.3% from 2024 to 2030

GlobeNewswire

a year ago

Global Upstream Bioprocessing Market Analysis Report 2024-2030: A $59.24 Billion Market by 2030, Registering a CAGR of 14.3% from 2024 to 2030

Eupraxia Pharmaceuticals Announces Voting Results from Annual General and Special Meeting of Shareholders

PR Newswire

a year ago

Eupraxia Pharmaceuticals Announces Voting Results from Annual General and Special Meeting of Shareholders

Eupraxia Pharmaceuticals to Present Data from the Phase 2 SPRINGBOARD Study in Osteoarthritis of the Knee at EULAR European Congress of Rheumatology 2024

PR Newswire

a year ago

Eupraxia Pharmaceuticals to Present Data from the Phase 2 SPRINGBOARD Study in Osteoarthritis of the Knee at EULAR European Congress of Rheumatology 2024

Eupraxia Pharmaceuticals Announces Expansion of RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic Esophagitis

CNW Group

a year ago

Eupraxia Pharmaceuticals Announces Expansion of RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic Esophagitis

Eupraxia Pharmaceuticals to Host Virtual KOL Event on EP-104GI Clinical Development Program for Eosinophilic Esophagitis ("EoE") on May 29, 2024

PR Newswire

a year ago

Eupraxia Pharmaceuticals to Host Virtual KOL Event on EP-104GI Clinical Development Program for Eosinophilic Esophagitis ("EoE") on May 29, 2024

Eupraxia Pharmaceuticals Announces New Positive Data from RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic Esophagitis

PR Newswire

a year ago

Eupraxia Pharmaceuticals Announces New Positive Data from RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic Esophagitis

Eupraxia Pharmaceuticals Announces New Positive Data from RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic Esophagitis

CNW Group

a year ago

Eupraxia Pharmaceuticals Announces New Positive Data from RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic Esophagitis

Eupraxia Pharmaceuticals to Present Initial Results from Ongoing Phase 1b Study of EP-104GI for the Treatment of Eosinophilic Esophagitis at Upcoming Digestive Disease Week Annual Meeting 2024

PR Newswire

a year ago

Eupraxia Pharmaceuticals to Present Initial Results from Ongoing Phase 1b Study of EP-104GI for the Treatment of Eosinophilic Esophagitis at Upcoming Digestive Disease Week Annual Meeting 2024

Eupraxia Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update

CNW Group

a year ago

Eupraxia Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update

Eupraxia Pharmaceuticals Announces Gastrointestinal Clinical Advisory Board

CNW Group

a year ago

Eupraxia Pharmaceuticals Announces Gastrointestinal Clinical Advisory Board

Eupraxia Pharmaceuticals Announces Upcoming Presentations at the Osteoarthritis Research Society International World Congress 2024

CNW Group

a year ago

Eupraxia Pharmaceuticals Announces Upcoming Presentations at the Osteoarthritis Research Society International World Congress 2024

Eupraxia Pharmaceuticals To Present at Bloom Burton & Co. Healthcare Investor Conference

PR Newswire

a year ago

Eupraxia Pharmaceuticals To Present at Bloom Burton & Co. Healthcare Investor Conference

Share on Social Networks: